Table 2.
Univariate analysis: factors associated with SVR–ITT analysis
| Characteristic | SVR | No SVR | P value |
|---|---|---|---|
| Number of subjects | 211 (54%) | 181 (46%) | |
| Age (years) | 48.2 ± 10.1 | 50.9 ± 8.8 | 0.004 |
| No. of males | 134 (64%) | 125 (69%) | 0.293 |
| Race | |||
| Asian (Non-South) | 31 (79%) | 8 (21%) | 0.003 |
| South Asian | 19 (56%) | 15 (44%) | |
| Caucasian | 161 (51%) | 158 (49%) | |
| Genotype | |||
| 1 | 113 (54%) | 147 (81%) | <0.001 |
| 2 | 41 (19%) | 9 (5%) | |
| 3 | 57 (27%) | 25 (14%) | |
| Pretreatment viral load (log10 IU/ml) | 5.8 ± 0.8 | 5.9 ± 0.5 | 0.081 |
| Weight (kg) | 75.2 ± 15.7 | 81.1 ± 16.7 | <0.001 |
| BMI (kg/m2) | 26.1 ± 5.0 | 27.9 ± 4.9 | <0.001 |
| Obese (WHO definition) | 33 (17%) | 43 (28%) | 0.029 |
| Obese (Asian definition) | 38 (20%) | 49 (32%) | 0.019 |
| Diabetes (Type 1 or 2) | 15 (7%) | 22 (12%) | 0.109 |
| Advanced Fibrosis (F3–F4 or clinical features of cirrhosis) | 105 (54%) | 103 (61%) | 0.255 |
| Steatosis ≥10% | 43 (24%) | 50 (33%) | 0.107 |
| Treatment naïve status | 194 (92%) | 135 (75%) | <0.001 |
| PegIFN 2a | 134 (64%) | 99 (55%) | 0.095 |
| Calculated ribavirin dose received (mg/kg/day) | 13.0 ± 2.7 | 12.8 ± 2.5 | 0.359 |
| Received “adequate” therapy (>80% dose, 80% duration) | 189 (90%) | 153 (85%) | 0.130 |
Data are expressed as n (%) or mean ± SD